These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35746530)

  • 21. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.
    Lijeskić O; Klun I; Stamenov Djaković M; Gligorić N; Štajner T; Srbljanović J; Djurković-Djaković O
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine.
    Ferenci T; Sarkadi B
    BMC Infect Dis; 2022 Jan; 22(1):87. PubMed ID: 35073866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study.
    Safarnezhad Tameshkel F; Abedin Dargoush S; Amirkalali B; Javadi S; Ghiaseddin A; Alimohamadi Y; Basi A; Jamshidi Makiani M; Zamani F; Karbalaie Niya MH
    Front Med (Lausanne); 2022; 9():1095194. PubMed ID: 36743671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered T-cell receptor β repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.
    Quan Z; Qi A; Ma S; Li Y; Chen H; Yu X; Dong T; Li K; Qiu Y
    Mol Immunol; 2023 Oct; 162():54-63. PubMed ID: 37647774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
    Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population.
    Kundro MA; Losso MH; Macchia A; Pastor I; Alonso Serena M; Gestoso C; Moreno Macías L; Crupi F; Acosta MC; Ivalo S; Ghioldi M; Bouzas MB; Mammana L; Zapiola I; Mazzitelli I; Varese A; Geffner J; Biscayart C; Angeleri P; Lopez E; Gentile A; Ferrante D; de Quiros FGB
    Public Health Pract (Oxf); 2022 Dec; 4():100313. PubMed ID: 36090797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
    Nadeem I; Ul Munamm SA; Ur Rasool M; Fatimah M; Abu Bakar M; Rana ZK; Khatana UF; Jordon L; Saqlain M; Mahdi N; McLoughlin H
    Postgrad Med J; 2023 Jun; 99(1171):463-469. PubMed ID: 37294716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
    Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
    Front Immunol; 2022; 13():967051. PubMed ID: 36159863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
    Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
    Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials.
    Macchia A; Ferrante D; Bouzas MB; Angeleri P; Biscayart C; Geffner J; Mammana L; Zapiola I; López EL; Gentile A; Varese A; Mazzitelli I; García FDD; Sharff D; Lucconi V; Sujansky P; Mariani J; de Quirós FGB
    Lancet Reg Health Am; 2022 May; 9():100196. PubMed ID: 35128512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
    Chen H; Huang Z; Chang S; Hu M; Lu Q; Zhang Y; Wang H; Xiao Y; Wang H; Ge Y; Zou Y; Cui F; Han S; Zhang M; Wang S; Zhu X; Zhang B; Li Z; Ren J; Chen X; Ma R; Zhang L; Guo X; Luo L; Sun X; Yang X
    Vaccine; 2022 Aug; 40(36):5322-5332. PubMed ID: 35931636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.
    Mahmoud S; Ganesan S; Sharif-Askari NS; Cantarutti F; Wilson H; Ogrodzki P; Halwani R; Alkaabi N; Zaher WA
    Curr Med Res Opin; 2022 Dec; 38(12):2069-2075. PubMed ID: 36274640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
    Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
    Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.